OrderMedications.org - buy hundreds cheap rx medicines online!

At the internet pharmacy you can buy discreetly shipped vytorin tablets and it will cost you considerably less!

Generic Vytorin Simvastatin ezetimibe 10mg + 10/20mg + 10mg

Vytorin 10/40, (ezetimibe 10 mg/simvastatin 40 mg tablets) are white to off-white capsule-shaped tablets with code "313" on one side. In clinical trials, there was no excess of myopathy or rhabdomyolysis associated with ezetimibe compared with the relevant control arm (placebo or statin alone). These elevations in transaminases were generally asymptomatic, not associated with cholestasis, and returned to baseline after discontinuation of therapy or with continued treatment. It is recommended that liver function tests be performed before the initiation of treatment with Vytorin, and thereafter when clinically indicated.

Package	Price	Per Pill	Order
10mg + 10mg × 30 pills	$78.20	US $ 2.61
10mg + 10mg × 60 pills	$146.40	US $ 2.44
10mg + 10mg × 90 pills	$198.60	US $ 2.21
10mg + 10mg × 120 pills	$250.80	US $ 2.09
10mg + 10mg × 180 pills	$355.20	US $ 1.97

Package	Price	Per Pill	Order
20mg + 10mg × 30 pills	$110.40	US $ 3.68
20mg + 10mg × 60 pills	$214.80	US $ 3.58
20mg + 10mg × 90 pills	$301.20	US $ 3.35
20mg + 10mg × 120 pills	$387.60	US $ 3.23

Warnings And Precautions

Patients titrated to the 10/80-mg dose should receive an additional test prior to titration, 3 months after titration to the 10/80-mg dose, and periodically thereafter (e.g., semiannually) for the first year of treatment. Simvastatin Simvastatin was not teratogenic in rats or rabbits at doses (25, 10 mg/kg/day, respectively) that resulted in 3 times the human exposure based on mg/m surface area. Because a small amount of another drug in this class is excreted in human milk and because of the potential for serious adverse reactions in nursing infants, women taking simvastatin should not nurse their infants. A decision should be made whether to discontinue nursing or discontinue drug, taking into account the importance of the drug to the mother In rat studies, exposure to ezetimibe in nursing pups was up to half of that observed in maternal plasma.

Use In Specific Populations

Of the 10,189 patients who received Vytorin in clinical studies, 3242 (32%) were 65 and older (this included 844 (8%) who were 75 and older). Vytorin Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. In the Vytorin (ezetimibe/simvastatin) placebo-controlled clinical trials database of 1420 patients (age range 20-83 years, 52% women, 87% Caucasians, 3% Blacks, 5% Hispanics, 3% Asians) with a median treatment duration of 27 weeks, 5% of patients on Vytorin and 2.2% of patients on placebo discontinued due to adverse reactions.

Adverse Reactions

In the event of an overdose, symptomatic and supportive measures should be employed. Ezetimibe In clinical studies, administration of ezetimibe, 50 mg/day to 15 healthy subjects for up to 14 days, or 40 mg/day to 18 patients with primary hyperlipidemia for up to 56 days, was generally well tolerated. A few cases of overdosage have been reported; most have not been associated with adverse experiences. Reported adverse experiences have not been serious. Simvastatin Significant lethality was observed in mice after a single oral dose of 9 g/m. No evidence of lethality was observed in rats or dogs treated with doses of 30 and 100 g/m, respectively.

Clinical Trials Experience

The most common adverse reactions in the group treated with Vytorin that led to treatment discontinuation and occurred at a rate greater than placebo were: Increased ALT (0.9%) Myalgia (0.6%) Increased AST (0.4%) Back pain (0.4%) The most commonly reported adverse reactions (incidence greater than 2% and greater than placebo) in controlled clinical trials were: headache (5.8%), increased ALT (3.7%), myalgia (3.6%), upper respiratory tract infection (3.6%), and diarrhea (2.8%).